A rough but useful organizing question: what does it bind?
One way to orient in the research-peptide field is to ask how well-defined a compound's molecular target is. At one end are peptides that act on a single, well-characterized cognate receptor with predictable pharmacology — the incretin class: semaglutide binds the GLP-1 receptor, tirzepatide binds the GLP-1 and GIP receptors, and retatrutide adds the glucagon receptor. Their pathways are described tightly because the receptor is known.
At the other end are peptides with no single established cognate receptor, which are studied as acting through more diffuse, indirect, or multiple targets — for example, BPC-157 modulates VEGFR2 signaling without an established direct receptor; Thymosin β4 binds G-actin, a specific intracellular target rather than a surface receptor; and the Khavinson-class bioregulators (epitalon, pinealon) are studied for a proposed DNA-regulatory activity that is not firmly established. This is a spectrum, not a clean binary — and it describes how the research is structured, not what any compound does for a person.
What this does and doesn't tell you
Not having a single classical receptor does not make a mechanism vague — Thymosin β4's actin binding is highly specific. And target definition is not the same as evidence depth. A well-characterized receptor usually means the pharmacology is easier to describe and replicate; a less-defined target usually means the published mechanism is broader and more of the work is preclinical. But how much human data stands behind any given compound is a separate axis entirely.
For that separate axis, read the evidence field map, which sorts the catalog by depth of published research. Target definition tells you how specific the mechanism is; the field map tells you how much human evidence stands behind it. Both belong in an honest read, and neither should be mistaken for the other.
